Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 22 (1), 2023
Pp 1459 - 1473

Nutrition as Essential Treatment in Inflammation-An Updated Review Article

[1] Khaled Abdullah Alshebel,[2] Abdulrahman Mohammed Abdulrahman Al-Qarni,[3] Ali Ahmed Mohammed Sahari,[4] Jawaher Abdullah Alawad,[5] Sultanah Mohammed Aljaber,[6] Yasser Mahdi Alabdoon,[7] Abdulaziz Mohammed Alhussini,[8] Abdullah Ali Abdullah Aldhafyan,[9] Nawaf Mohammed Aldughaishem,[10] Nada Abdulaziz Faraj Alzaidi

1. Ksa, Ministry of Health, Al-Muznib General Hospital
2. Ksa, Ministry of Health, Al-Bashaier Hospital
3. Ksa, Ministry of Health, Alarda General Hospital
4. Ksa, Ministry of Health, Eradah complex and mental health-Riyadh
5. Ksa, Ministry of Health, Madinah Haram Hospital
6. Ksa, Ministry of Health, Riyadh long term care hospital
7. Ksa, Ministry of Health, Riyadh long term care hospital
8. Ksa, Ministry of Health, Aliman hospital
9. Ksa, Ministry of Health, Riyadh Health Cluster 3
10. Ksa, Ministry of Health, Ohud Hospital - Madina

Abstract:

Background: Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, immune-mediated disorder characterized by inflammation of the gastrointestinal tract. The relationship between diet, gut microbiota, and immune response is increasingly recognized as a key factor in the development and management of IBD. The Western diet, rich in fats, sugars, and additives, is thought to contribute to IBD progression. This review investigates dietary interventions aimed at modulating gut inflammation, focusing on their role in managing IBD.

Aim: This article aims to evaluate the effectiveness of dietary treatments, such as Exclusive Enteral Nutrition (EEN), Partial Enteral Nutrition (PEN), and the Crohn's Disease Exclusion Diet (CDED), in managing IBD, specifically focusing on their impact on inflammation, microbiota composition, and clinical outcomes.

Methods: A comprehensive search was conducted on clinical trial registries and the PUBMED database to identify relevant studies on dietary interventions for IBD. The review includes trials comparing dietary therapies to standard treatments, placebos, and other interventions, with a focus on clinical remission, mucosal healing, and microbial alterations.

Results: EEN has shown strong efficacy in inducing remission in pediatric CD patients, with higher mucosal healing rates compared to corticosteroids. While PEN combined with CDED has demonstrated similar remission rates to EEN, it offers advantages in patient tolerance and long-term management. Additionally, dietary changes were associated with shifts in gut microbiota, particularly a decrease in microbial diversity and changes in specific bacterial species, which are linked to clinical improvement.

Conclusion: Dietary interventions, especially EEN and PEN with CDED, are promising treatments for IBD, offering significant benefits in managing inflammation and promoting mucosal healing. Further research is needed to optimize these dietary strategies for both short- and long-term management of IBD.

Keywords: Inflammatory bowel disease, Crohn's disease, ulcerative colitis, Exclusive Enteral Nutrition, Partial Enteral Nutrition, Crohn's Disease Exclusion Diet, microbiota, inflammation.

Received: 05 october 2023 **Revised**: 19 November 2023 **Accepted**: 02 December 2023

Introduction:

The term "inflammatory bowel disease" (IBD) refers to a group of long-term, immune-mediated intestinal conditions. It is generally accepted that the intricate relationships between the intestinal microbiota and the host's immune system impact the development of IBD, even though the precise processes underlying the condition are still not fully known. The Western diet is thought to be a major factor in the development of IBD, as seen by the rising incidence of the condition in areas embracing Western lifestyles [1]. Dietary variables can influence the course of IBD, according to research [1,2]. This study offers a thorough analysis of the dietary approaches currently used to treat Ulcerative Colitis (UC) and Crohn's disease (CD), considering both the underlying inflammatory processes and clinical symptoms. To find pertinent studies, a thorough search of clinical trial registries and the PUBMED database was carried out. The evaluation includes trials that compared dietary interventions with standard therapy, other active treatments, placebos, or no treatment at all.

Impaired intestinal barrier function and changes in the makeup and function of the gut microbiota, which result in an activation of the intestinal immune system, are hallmarks of the pathophysiology of IBD [3]. Studies on both humans and animals have supported these conclusions, showing a clear link between food and microbiome dysbiosis, a typical symptom of IBD patients [4,5]. For example, *Enterobacteriaceae, Pasteurellaceae, Veillonellaceae, and Fusobacteriaceae are more abundant in CD patients, but species like Erysipelotrichales, Bacteroidales, and Clostridiales* are significantly less prevalent [6]. Reduced phylogenetic diversity and the loss of beneficial bacteria, along with an overabundance of Enterobacteriaceae and Enterococcus and a deficiency of Ruminococcus and Bacteroides, are the hallmarks of dysbiosis in UC [7,8,9]. The intestinal mucosal barrier is modulated in large part by diet [10]. High-fat and high-sugar diets caused dysbiosis in murine models of IBD, with an overabundance of E. coli, which resulted in intestinal permeability and mucosal disintegration [11]. Furthermore, several food additives that are frequently found in Western diets have been linked to the encouragement of intestinal inflammation. For instance, it has been demonstrated that modest quantities of the food emulsifier polysorbate 80 increase adherent-invasive E. coli (AIEC) translocation between intestinal M cells and Peyer's patches, which causes an inflammatory response [12]. Moreover, enhanced AIEC biofilm development has been linked to maltodextrin, a common dietary polysaccharide [13]. Studies on humans have shown comparable impacts on mucosal integrity and microbiota makeup. The gut microbiota's adaptability and response to dietary changes were demonstrated in an interventional experiment where notable shifts in microbiome diversity were observed within a day after dietary alteration [14]. Additionally, human randomized controlled trials indicate that food additives such thickeners and emulsifiers can be involved in intestinal inflammation [15,16]. Together, these results highlight the significant influence of food on gut microbiota and epithelial barrier function, indicating that dietary interventions could be a useful treatment approach for IBD.

In 2021, treatment goals for adult and pediatric IBD populations were suggested by the International Organization for the Study of Inflammatory Bowel Disease (ISO)-led Selecting Therapeutic Targets in Inflammatory Disease (STRIDE) effort [17]. Both short-term and long-term objectives for IBD management were highlighted by STRIDE-II. When assessing interventions, such as dietary therapies, it is essential to comprehend these goals. Resolution of symptoms is the main objective of short-term treatment, with normalization of inflammatory biomarkers serving as a target in between. Achieving mucosal healing and encouraging growth restoration are the main long-term goals. In CD, the level of mucosal inflammation seen by endoscopy does not always correspond with clinical symptoms. Treatment decisions are based on a composite approach that includes objective measures of inflammation, such as fecal calprotectin and C-reactive protein (CRP) levels, periodic colonoscopy restaging, and symptom monitoring using clinical activity indices, such as the Pediatric Crohn's Disease Activity Index (PCDAI)/Crohn's Disease Activity Index (CDAI) scores and the Harvey–Bradshaw Index (HBI). On the other hand, endoscopic inflammation is more

closely associated with clinical signs of UC, such as rectal bleeding and stool frequency. The Mayo Endoscopic Score (MES) is used to measure mucosal healing in UC, while the Pediatric Ulcerative Colitis Activity Index (PUCAI)/Mayo score is used for clinical evaluation. These metrics will be considered when assessing the efficacy of dietary interventions in this assessment of the most recent clinical evidence.



Figure 1: Nutrition in Cancer and Inflammation.

Exclusive Enteral Nutrition (EEN)

One of the most well-known, scientifically supported dietary treatments for Inflammatory Bowel Disease (IBD) is Exclusive Enteral Nutrition (EEN), which is used as a primary intervention to induce remission in juvenile patients with mild-to-moderate Crohn's disease (CD) [18]. The use of a comprehensive nutritional formula as the only source of nourishment for six to ten weeks is what defines EEN. Compared to corticosteroid therapy, this method has been demonstrated to provide a markedly higher rate of endoscopic mucosal healing and to produce clinical and biochemical remission in about 80% of pediatric CD patients [19, 20, 21, 22, 23]. Mucosal healing rates of 73% and 89%, respectively, have been reported in studies by Borelli et al. and Pigneur et al. However, studies conducted on adult populations show decreased efficacy, which could be due to both compliance problems and variations in illness manifestation. Interestingly, studies requiring nasogastric tube feeding showed efficacy comparable to that seen in juvenile populations, even though many adult research permitted oral intake of the formula [24, 25]. Furthermore, despite the retrospective character of current studies, there is growing interest in the function of EEN in preoperative optimization for CD, with positive implications [26]. Even though EEN is good at bringing about remission, "formula fatigue" makes it difficult to utilize for extended periods of time. Although EEN may benefit UC patients with their symptoms and nutritional status, there is currently no strong evidence to support its routine administration for causing remission in UC [27, 28]. To ascertain EEN's possible advantages in the therapy of UC, more investigation is required [29].

There is no one formula that has been shown to be more effective than others at causing clinical remission in CD, and the content of the formulas employed in EEN varies widely [30]. When compared to the dietary intake of children with chronic CD, an analysis of 61 EEN formulas used to induce remission in

active pediatric CD showed that EEN formulas typically had higher percentages of protein and lower levels of sugar, total fat, saturated fat, and fiber [30]. The fact that food additives in these formulae did not seem to affect remission rates suggests that EEN's efficacy may be influenced by the diet's monotonous aspect as much as its composition. Although the precise process by which EEN causes remission is still up for question, its effects on the gut microbiota are well-established, albeit occasionally at odds with accepted scientific wisdom. Contrary to the widely held belief that a diverse microbiome is advantageous for health, EEN therapy causes the intestinal microbiome's diversity to decline [33, 34]. In contrast to corticosteroids, EEN-induced remission results in greater rates of mucosal repair despite these changes. In contrast to corticosteroids, Pigneur et al. discovered that EEN-induced remission was linked to a different microbiota makeup [22]. Additionally, Firmicutes species implicated in CD, including Ruminococcus gnavus, Ruminococcus torques, and several Clostridium species, are paradoxically enriched by EEN [22, 35, 36]. A decrease in the Bifidobacterium species Faecalibacterium prausnitzii, which is essential for intestinal homeostasis, is also linked to EEN [37, 38]. Despite the fact that these microbial changes defy conventional scientific predictions, they are probably crucial for comprehending the ways in which EEN induces remission. Food emulsifiers such as carboxymethylcellulose and polysorbate-80 caused intestinal inflammation in animals with an intact microbiome, but not in germ-free mice, according to a study conducted using an IL-10 deletion mouse model [39]. EEN's direct impact on the inflammatory cascade and its influence on hormones like serum insulin-like growth factor 1 (IGF-1), transforming growth factor-beta (TGF-β1), and vascular endothelial growth factor (VEGF) are other hypothesized mechanisms for its role in mucosal healing [27, 40, 41]. According to Wedrychowicz et al., CD patients experience a quicker rate of disease remission when EEN promotes TGF-β1 compared to UC patients [27]. All of these serum alterations point to a systemic anti-inflammatory impact, which could account for the mucosal healing seen in patients receiving EEN.

Partial Enteral Nutrition (PEN) with and without an Exclusion Diet

A program known as partial enteral nutrition (PEN) involves consuming 50% to 90% of calories from formula and the remaining portion from real meals. In order to evaluate the effects of a regular diet in juvenile CD patients with active illness, Johnson et al. compared PEN and EEN. Fifty youngsters were randomly assigned to receive 50% PEN or 50% EEN in this trial. Although there were nutritional advantages and symptom improvement in both groups, PEN participants experienced noticeably lower remission rates (15 vs. 42%) [42]. A normal diet may worsen the inflammatory burden in CD, as the EEN group also shown better improvements in laboratory markers, such as lower erythrocyte sedimentation rates (ESR) and higher albumin levels. When paired with PEN, the Crohn's Disease Exclusion Diet (CDED) seeks to restrict items thought to have a deleterious impact on the intestinal flora, impair the function of the intestinal barrier, or cause inflammation in the colon. CDED excludes high-fat, dairy, sugary foods, artificial additives, and emulsifiers and promotes lean protein, resistant starch, and moderate fiber. During the induction and maintenance periods, this diet is combined with different dosages of PEN. According to clinical research, CDED and PEN together produce remission rates in adolescents and adults that are on par with EEN [43, 44, 45]. Levine et al. discovered that both PEN with CDED and EEN resulted in high remission rates and decreased inflammation after six weeks, with no discernible difference between the groups in a prospective 12-week pediatric trial. Compared to 59% in the EEN group, 75% of children receiving CDED with PEN were in steroid-free remission at this time point ($p = 0.38$). Additionally, fewer study withdrawals occurred with the CDED plus PEN regimen, indicating improved patient tolerance (97.5% vs. 73.6%).

The potential of CDED as a rescue treatment for CD patients who have not responded to biologic medicines was investigated by Sigall Boneh et al. Clinical responses were observed in 19 out of 21 individuals in a short research with 10 adolescents and 11 adults; 13 of these patients experienced remission as determined by the Harvey-Bradshaw Index (HBI). At the 12-week follow-up, C-reactive protein (CRP) levels had significantly decreased [46]. In a recent pilot research, Yanai et al. found that CDED, with or without PEN, successfully elicited and maintained remission in people with mild-to-moderate, biologic-naive CD. 57% of patients in the CDED-only group and 68% of individuals in the CDED plus PEN group experienced clinical remission at six weeks. Thirty-five percent of patients exhibited endoscopic remission

at week 24, and eighty percent of those in remission at week six maintained remission at week 24 [45]. The intestinal microbiota and metabolome undergo significant alterations when CDED and PEN are combined. According to a recent study by Verburgt et al., EEN-induced remission and CDED with PEN were linked to higher Firmicutes levels and lower Proteobacteria abundance. Furthermore, a combination of the M1 and M2 metabotypes was seen in CD patients. While M2 was linked to high Proteobacteria and SCFA degradation, M1 was characterized by high Bacteroidetes and Firmicutes, low Proteobacteria, and increased production of small-chain fatty acids (SCFAs). In CD patients, metabotype M1's contribution rose from 48% to 74% at 12 weeks [47]. Additionally, there were notable changes in metabolites, such as kynurenine and ceramides, which are connected to active CD, in remission linked to both CDED with PEN and EEN [48]. These results offer PEN with CDED as a possibly more durable option than EEN for long-term dietary management in IBD and support the idea of dietary restriction as a way to preserve remission.

Whole Foods and Exclusion Diets

As the influence of diet on Inflammatory Bowel Disease (IBD) continues to gain recognition, the International Organization for the Study of Inflammatory Bowel Disease (IOSIBD) conducted a review of the current evidence regarding the potentially harmful and beneficial dietary components for Crohn's Disease (CD) and Ulcerative Colitis (UC) [49]. For CD, the IOSIBD recommended the regular intake of fruits and vegetables, provided structuring disease was absent. In the case of UC, an increased intake of natural omega-3 fatty acids (as opposed to supplements) was suggested as potentially beneficial. For both conditions, the general guidance was to reduce the consumption of saturated fats, trans fats, dairy fats, food additives (such as polysorbate 80 and carboxymethylcellulose), processed foods containing maltodextrins, and artificial sweeteners such as sucralose and saccharine. Additionally, the IOSIBD acknowledged that patients with persistent symptoms despite the resolution of inflammation might benefit from a low FODMAP or lactose-free diet. However, they noted the lack of sufficient research to make recommendations concerning the intake of gluten, poultry, alcohol, or refined sugars, suggesting the need for further randomized controlled trials.

Ongoing Clinical Research on Exclusionary Whole Food Diets: SCD, FODMAP, and the Mediterranean Diet

Specific Carbohydrate Diet (SCD)

Dr. Sydney Haas, a physician, created the Specific Carbohydrate Diet (SCD) in the 1930s to treat celiac disease. All grains, processed foods, sweets (save honey), and the majority of dairy products—aside from properly fermented yogurt and some hard cheeses—are prohibited in the diet. Following the successful treatment of Elaine Gottschall's daughter for Ulcerative Colitis (UC) in the 1990s, the diet became even more well-known. Moreover, a considerable number of IBD patients have shown support for the diet. According to a survey of 417 IBD patients in children and adults who followed the SCD, 36% of them experienced clinical remission in one to three months, while another 34% did so after more than three months. Improvements in aberrant laboratory results were reported by 47% of individuals who achieved remission [50].

Between 2005 and 2012, Suskind et al. at Seattle Children's Hospital carried out the first chart evaluation of the SCD in children with active Crohn's disease (CD). According to the study, within 12 weeks, patients on the SCD had a resolution of their symptoms and a return to normal of important biomarkers, including albumin, anemia, fecal calprotectin, and C-reactive protein (CRP) [51]. Following 12 weeks of SCD, Cohen et al. used capsule endoscopy to show small intestinal mucosal repair in a group of nine young CD patients [52]. From 2012 to 2014, Seattle Children's Hospital carried out another retrospective assessment that looked at the results of 26 individuals on the SCD (20 with CD and 6 with UC). Erythrocyte sedimentation rate (ESR), CRP, and fecal calprotectin levels decreased in CD patients, while their Pediatric Crohn's Disease Activity Index (PCDAI) scores improved. Additionally, UC patients' Pediatric Ulcerative Colitis Activity Index (PUCAI) ratings improved, and their laboratory results either improved or stayed normal. Some patients lost weight while following the diet, despite these clinical and scientific advancements, and many of them progressively added more foods to their regimen, including rice, oatmeal, potatoes, and cocoa powder.

Suskind et al.'s prospective 12-week trial in children with active CD and UC confirmed the biochemical and clinical benefits of SCD while also observing notable alterations in the microbial makeup. In particular, CRP levels decreased in both the Seattle and Atlanta patient groups, and the mean PCDAI and PUCAI scores normalized from baseline to 12 weeks [54]. Suskind et al. carried out a small, randomized trial comparing the SCD, modified SCD, and a healthy whole foods diet in active CD patients in order to examine the effect of dietary exclusion on clinical results. According to the study, improved inflammation resolution was linked to diets that were more restrictive. Accordingly, in children with active IBD, the PRODUCE study, a sizable multicenter trial, contrasted the SCD with the modified SCD. There was no discernible difference between the two diets, even though both showed advantages above a typical diet in terms of calprotectin levels and symptom control. Although there was no discernible difference between the two diets, a different adult investigation called the DiNE-CD trial showed that both the SCD and Mediterranean Diet (MD) improved symptoms in patients with active CD [57]. Although changes in the gut microbiome have been noted after SCD treatment, no consistent effect on microbiome diversity has been demonstrated due to the small sample sizes. After two weeks on the diet, four out of nine patients in a research by Suskind et al. showed an increase in microbial diversity, albeit the changes were slight. Proteobacteria levels dropped in the majority of patients, however Faecalibacterium prausnitzii levels significantly increased in one patient, rising from 9.6% to 54%. However, there were no notable changes in the general composition of the microbiome [54]. In a more recent trial, Shabat et al. looked at patients who were not responding to medical therapy and the Ulcerative Colitis Exclusion Diet (UCED) with or without fecal microbiota transplantation (FMT). Compared to single-donor FMT, UCED alone produced greater rates of mucosal healing and clinical remission; after eight weeks, 26% of patients showed endoscopic remission and 40% of patients experienced clinical remission [58].

Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAPs) Diet

Because FODMAPs are fermented in the colon and poorly absorbed in the small intestine, they may cause symptoms in IBD patients that are comparable to those of Irritable Bowel Syndrome (IBS). A low-FODMAP diet (LFD) has been shown in numerous trials to improve the quality of life for those with IBD and lessen symptoms similar to the disease [59,60,61]. A research by Cox et al. examined IBD patients who were in remission but still had functional gastrointestinal symptoms that satisfied the Rome III criteria for IBS. These patients had previously demonstrated improvement on the LFD, and they developed gastrointestinal symptoms when challenged with fructans, but not with galacto-oligosaccharides or sorbitol [62].

In a single-blind trial with quiescent IBD patients, Cox et al. conducted additional research and discovered that a higher proportion of patients on the LFD reported improvements in intestinal symptoms (52%) than those on the diet control (16%), with a significant decrease in IBS severity scores. However, this change was not statistically significant. Furthermore, compared to patients on the control diet, those on the LFD reported superior health-related quality of life scores [63]. When compared to the normal diet, the LFD significantly decreased HBi scores in a randomized 6-week experiment conducted by Bodini et al. with 55 adult IBD patients receiving biologic therapy [64].

Although the intestinal microbiome is impacted by the LFD, it is unknown how this will affect the diversity of the microbiome. The LFD in IBS did not consistently affect microbiome indicators like diversity, fecal short-chain fatty acid (SCFA) concentrations, or fecal pH, according to a meta-analysis of nine randomized controlled trials. Nonetheless, certain changes were noted in the Bifidobacteria, including decreases in species like Faecalibacterium prausnitzii, Bifidobacterium longum, and Bifidobacterium adolescentis [63]. Despite these changes, there was no discernible effect on microbial diversity or inflammatory indicators. These results imply that while the LFD does not seem to lessen inflammation in people with active IBD, it may be helpful for quiescent patients who have ongoing IBS-like symptoms. Therefore, only patients with concurrent IBS and quiescent IBD should be evaluated for the LFD.

The Mediterranean Diet (MD):

The Mediterranean Diet (MD) has gained significant attention due to its numerous health benefits, particularly its anti-inflammatory properties, which have been linked to reduced risks of cardiovascular disease, cancer, and other chronic conditions. This diet is characterized by a high intake of vegetables, fruits, cereals, nuts, legumes, and unsaturated fats, with moderate consumption of fish and dairy, while limiting saturated fats, meat, and sweets. Its potential in managing inflammatory bowel disease (IBD) has also been explored in various studies. One study by Chicco et al. (2018) investigated the impact of MD on IBD patients over six months. The findings showed that MD was associated with a reduction in body mass index (BMI), waist circumference, and liver steatosis, while also improving disease activity markers like CDAI and Mayo scores, as well as lowering CRP and fecal calprotectin levels. Additionally, improvements in quality of life were reported for patients with Crohn's disease (CD) and ulcerative colitis (UC). Similar results were seen in patients with UC following pouch surgery who adhered to MD, showing a reduction in fecal calprotectin levels.

Strisciuglio et al. (2019) conducted a study involving pediatric patients with CD and UC, demonstrating that the MD significantly reduced fecal calprotectin, a biomarker of intestinal inflammation. Moreover, a comparative study by Lewis et al. (2019) involving adults with CD found that the MD was as effective as the Specific Carbohydrate Diet (SCD) in reducing symptoms and inflammatory markers, with comparable effects on fecal calprotectin and CRP. The intestinal microbiome showed minimal differences between the two diets, further supporting the viability of MD as a simpler, more accessible alternative to other restrictive diets. Integrating dietary interventions into the care of IBD patients is crucial for improving clinical outcomes. However, while there is growing evidence supporting the use of diets like MD in IBD management, they are still not routinely implemented in patient care. Dietary therapies, much like medical treatments, require careful planning, clear goals, and guidance from a dietitian. Each patient's diet plan should be personalized, considering the severity of their condition and their overall health. Despite the progress in dietary research for IBD, there remains much to explore. Future studies should aim to further elucidate the mechanisms through which diet influences IBD, particularly by examining immune responses, microbiota composition, and nutritional pathways.

By combining immunology, microbiology, and genomics, researchers can uncover deeper insights into how specific dietary interventions work. With continued research and integration of diet into clinical practice, dietary interventions hold the potential to significantly shift the paradigm in IBD management [69-71].

Future Directions in Nutrition for the Treatment of Inflammation in Inflammatory Bowel Disease (IBD)

The role of nutrition in the management of Inflammatory Bowel Disease (IBD) has garnered increasing attention over the past decade. Nutrition therapy has the potential to play a crucial role in modulating inflammatory responses, supporting immune function, and improving overall disease management in IBD patients. As IBD is a chronic, relapsing condition characterized by inflammation of the gastrointestinal tract, the integration of nutrition as part of the treatment plan is an area ripe for exploration. While current research has shown promising results, several avenues remain unexplored, and future studies are essential to better define the mechanisms by which nutrition influences disease processes, how it can be integrated into clinical practice, and how it can contribute to personalized treatment strategies [71].

Exploring Mechanisms of Dietary Influence on Inflammation

Understanding the mechanisms through which diet affects inflammation is crucial for advancing nutrition therapy in IBD management. Inflammation in IBD is driven by a dysregulated immune response, wherein the body's immune system attacks the intestinal mucosa. Specific dietary interventions, such as the Mediterranean Diet (MD), enteral nutrition (EEN), and the Specific Carbohydrate Diet (SCD), have shown varying degrees of success in modulating inflammation. However, the exact biochemical pathways and cellular processes remain poorly understood. Future research should focus on elucidating the immune-

modulating effects of different dietary components. A growing body of evidence suggests that dietary fats, fiber, and proteins significantly influence intestinal immune responses. For example, unsaturated fats, as found in the Mediterranean Diet, are postulated to have anti-inflammatory properties, while high-fiber diets can support the growth of beneficial gut microbiota, which may further regulate immune function. Investigating how specific micronutrients, such as omega-3 fatty acids, antioxidants, and vitamins, impact inflammatory pathways and cytokine profiles will be essential to develop targeted nutritional interventions for IBD. In addition, examining the interaction between diet and the gut microbiome offers another promising avenue. The gut microbiota plays a central role in modulating immune responses and maintaining intestinal homeostasis. Disruptions in microbiome composition, referred to as dysbiosis, have been linked to the pathogenesis of IBD. Diet can shape the microbiome by providing nutrients that support beneficial bacteria while suppressing pathogenic microbes. Future research should employ metagenomic and microbiome analysis techniques to investigate how dietary interventions influence gut microbial diversity and its subsequent impact on inflammation. This could pave the way for microbiome-based personalized nutrition therapies that could enhance disease remission and prevent flare-ups.

Precision Nutrition and Personalized Diet Plans

The concept of personalized medicine is increasingly becoming a critical focus in the treatment of IBD. Each patient's response to dietary interventions is influenced by a variety of factors, including genetics, gut microbiota composition, and disease severity. Personalized nutrition, where dietary interventions are tailored to an individual's specific needs, holds the potential to improve clinical outcomes in IBD patients. To make personalized nutrition a reality, future studies should investigate the genetic and epigenetic factors that influence patients' responses to different diets. Nutrigenomics, the study of how genetic variations affect individual responses to diet, is a promising field. By understanding the genetic predispositions that impact how patients metabolize certain nutrients, healthcare providers can develop more precise dietary recommendations. For example, individuals with certain genetic polymorphisms may respond better to high-fiber diets or specific fatty acid compositions, while others may benefit more from low-residue or exclusionary diets. Additionally, identifying biomarkers for dietary response will be essential for developing personalized nutrition plans. Studies have already demonstrated that inflammatory markers like C-reactive protein (CRP) and fecal calprotectin can reflect the level of inflammation in IBD patients. By linking these biomarkers to dietary interventions, clinicians could more effectively monitor patient responses to nutrition therapy, allowing for timely adjustments to the dietary plan.

Integrating Nutrition into Clinical Practice

Despite the growing body of evidence supporting the use of diet in IBD management, nutritional interventions are still not routinely integrated into standard patient care. One key challenge is the lack of formalized guidelines for incorporating diet into IBD treatment protocols. Future research should aim to establish evidence-based dietary guidelines tailored to different stages of IBD, from the induction of remission to the maintenance phase. These guidelines should consider not only the patient's disease activity but also their nutritional status, comorbidities, and preferences. Training healthcare professionals, including gastroenterologists, dietitians, and nurses, is essential for improving the integration of nutrition into IBD care. The multidisciplinary approach is crucial, as dieticians play an integral role in educating patients on food choices and ensuring that nutritional plans align with medical treatments. Furthermore, enhancing patient awareness and understanding of the role of nutrition in disease management is critical. Patient-centered education initiatives could empower individuals with IBD to make informed dietary choices that complement their medical treatment, ultimately improving quality of life and long-term disease outcomes.

Future Directions in Clinical Trials and Research

In addition to expanding our understanding of the mechanisms of dietary effects on IBD, there is a need for large-scale, long-term clinical trials to assess the efficacy of various diets in diverse patient populations. While many studies have shown promising results for specific dietary patterns, most have

been small in scale or of limited duration. Large, multi-center, randomized controlled trials (RCTs) that include a wide range of patient demographics, including different age groups, ethnicities, and stages of disease, are necessary to establish the generalizability and long-term benefits of dietary interventions.

Future trials should also focus on comparing the effectiveness of different diets, not just in terms of symptom management, but also in terms of long-term outcomes such as disease progression, surgery rates, and medication use. While diets like EEN and MD have shown positive effects on disease remission, the comparative effectiveness of these diets versus traditional medical therapies (e.g., biologics, corticosteroids) remains underexplored. Research in this area will be essential for determining whether dietary interventions can serve as a standalone therapy or as an adjunct to pharmacologic treatments. As research in the field of nutrition and IBD advances, we are moving closer to a more comprehensive understanding of how diet can be used to manage and even modify the course of this chronic condition. The future of nutrition in IBD treatment lies in personalized, evidence-based approaches that integrate genetic, microbiological, and immunological insights. By continuing to explore the underlying mechanisms of diet's effects on inflammation, and by establishing clear guidelines and protocols for clinical practice, nutrition can become a cornerstone of IBD management. With the growing evidence supporting its benefits, dietary interventions have the potential to transform the landscape of IBD care, offering patients a powerful tool to complement medical therapies and improve their quality of life.

Conclusion:

The growing body of evidence suggests that nutrition plays a critical role in the management of inflammatory bowel disease (IBD), particularly in modulating the inflammatory processes that underpin the condition. Dietary interventions, such as Exclusive Enteral Nutrition (EEN), Partial Enteral Nutrition (PEN), and the Crohn's Disease Exclusion Diet (CDED), have shown promise in inducing remission and improving clinical outcomes in patients with Crohn's disease (CD) and ulcerative colitis (UC). EEN remains one of the most well-supported dietary treatments for pediatric patients with mild-to-moderate CD. By using a specialized nutritional formula as the sole source of nutrition for several weeks, EEN can significantly enhance mucosal healing and achieve clinical remission, even surpassing the efficacy of corticosteroids in some cases. This dietary approach, although challenging in terms of patient compliance, especially due to the monotony of the formula, has been shown to produce substantial benefits in restoring intestinal health. Moreover, EEN is believed to modulate the gut microbiota, albeit in ways that challenge the conventional understanding of microbiome diversity. While it leads to a reduction in microbial diversity, this change is not necessarily detrimental to clinical outcomes and may even be a key factor in its success. Partial Enteral Nutrition (PEN) combined with CDED offers a viable alternative for long-term IBD management. This approach, which combines a formula-based diet with real foods, has shown comparable results to EEN inducing remission. PEN with CDED also appears to offer better patient tolerance, reducing the incidence of formula fatigue and improving overall dietary compliance. CDED's exclusion of foods thought to exacerbate IBD, such as high-fat, dairy, and processed foods, alongside its emphasis on lean proteins and resistant starch, supports gut barrier integrity and reduces inflammation. The combination of PEN and CDED has also demonstrated promise in maintaining remission, particularly in biologic-naïve patients and those who have not responded to traditional therapies. Research indicates that this approach can result in substantial reductions in C-reactive protein (CRP) levels and improvements in clinical indices of disease activity. Furthermore, the combination of these dietary strategies with changes in the gut microbiota and metabolome provides insight into their underlying mechanisms of action. The shifts in microbial composition, including increased levels of Firmicutes and decreased Proteobacteria, suggest a more favorable environment for gut healing. Overall, while dietary interventions show considerable potential, further research is essential to fully elucidate their mechanisms and optimize their use in clinical practice. In particular, understanding the long-term impacts of these diets on microbiota composition, immune function, and overall gut health will be crucial in establishing standardized guidelines for their implementation. Given the complexity of IBD and its multifactorial nature, personalized dietary treatments tailored to individual patients' needs and disease characteristics are likely to yield the best outcomes in managing this chronic condition.

References:

1. Adolph, T.E.; Zhang, J. Diet fuelling inflammatory bowel diseases: Preclinical and clinical concepts. *Gut* **2022**, *71*, 2574–2586.
2. Cusimano, F.A.; Damas, O.M. Diet as a treatment for inflammatory bowel disease: Is it ready for prime time? *Curr. Opin. Gastroenterol.* **2022**, *38*, 358–372.
3. Levine, A.; Sigall Boneh, R.; Wine, E. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. *Gut* **2018**, *67*, 1726–1738.
4. Peterson, D.A.; Frank, D.N.; Pace, N.R.; Gordon, J.I. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. *Cell Host Microbe* **2008**, *3*, 417–427.
5. Ott, S.J.; Schreiber, S. Reduced microbial diversity in inflammatory bowel diseases. *Gut* **2006**, *55*, 1207.
6. Gevers, D.; Kugathasan, S.; Denson, L.A.; Vazquez-Baeza, Y.; Van Treuren, W.; Ren, B.; Schwager, E.; Knights, D.; Song, S.J.; Yassour, M.; et al. The treatment-naive microbiome in new-onset Crohn's disease. *Cell Host Microbe* **2014**, *15*, 382–392.
7. Rajilic-Stojanovic, M.; Shanahan, F.; Guarner, F.; de Vos, W.M. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. *Inflamm. Bowel Dis.* **2013**, *19*, 481–488.
8. Nemoto, H.; Kataoka, K.; Ishikawa, H.; Ikata, K.; Arimochi, H.; Iwasaki, T.; Ohnishi, Y.; Kuwahara, T.; Yasutomo, K. Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. *Dig. Dis. Sci.* **2012**, *57*, 2955–2964.
9. Angelberger, S.; Reinisch, W.; Makristathis, A.; Lichtenberger, C.; Dejaco, C.; Papay, P.; Novacek, G.; Trauner, M.; Loy, A.; Berry, D. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. *Am. J. Gastroenterol.* **2013**, *108*, 1620–1630.
10. Lane, E.R.; Zisman, T.L.; Suskind, D.L. The microbiota in inflammatory bowel disease: Current and therapeutic insights. *J. Inflamm. Res.* **2017**, *10*, 63–73.
11. Martinez-Medina, M.; Denizot, J.; Dreux, N.; Robin, F.; Billard, E.; Bonnet, R.; Darfeuille-Michaud, A.; Barnich, N. Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. *Gut* **2014**, *63*, 116–124.
12. Roberts, C.L.; Keita, A.V.; Duncan, S.H.; O'Kennedy, N.; Soderholm, J.D.; Rhodes, J.M.; Campbell, B.J. Translocation of Crohn's disease Escherichia coli across M-cells: Contrasting effects of soluble plant fibres and emulsifiers. *Gut* **2010**, *59*, 1331–1339.
13. Nickerson, K.P.; McDonald, C. Crohn's disease-associated adherent-invasive Escherichia coli adhesion is enhanced by exposure to the ubiquitous dietary polysaccharide maltodextrin. *PLoS ONE* **2012**, *7*, e52132.
14. Wu, G.D.; Chen, J.; Hoffmann, C.; Bittinger, K.; Chen, Y.Y.; Keilbaugh, S.A.; Bewtra, M.; Knights, D.; Walters, W.A.; Knight, R.; et al. Linking long-term dietary patterns with gut microbial enterotypes. *Science* **2011**, *334*, 105–108.]
15. Bhattacharyya, S.; Shumard, T.; Xie, H.; Dodda, A.; Varady, K.A.; Feferman, L.; Halline, A.G.; Goldstein, J.L.; Hanauer, S.B.; Tobacman, J.K. A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity. *J. Nutr. Health Aging* **2017**, *4*, 181–192.
16. Chassaing, B.; Compher, C.; Bonhomme, B.; Liu, Q.; Tian, Y.; Walters, W.; Nessel, L.; Delaroque, C.; Hao, F.; Gershuni, V.; et al. Randomized Controlled-Feeding Study of Dietary Emulsifier Carboxymethylcellulose Reveals Detrimental Impacts on the Gut Microbiota and Metabolome. *Gastroenterology* **2022**, *162*, 743–756.

17. Turner, D.; Ricciuto, A.; Lewis, A.; D'Amico, F.; Dhaliwal, J.; Griffiths, A.M.; Bettenworth, D.; Sandborn, W.J.; Sands, B.E.; Reinisch, W.; et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. *Gastroenterology* **2021**, *160*, 1570–1583.

18. Ruemmele, F.M.; Veres, G.; Kolho, K.L.; Griffiths, A.; Levine, A.; Escher, J.C.; Amil Dias, J.; Barabino, A.; Braegger, C.P.; Bronsky, J.; et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. *J. Crohns Colitis* **2014**, *8*, 1179–1207.

19. Yu, Y.; Chen, K.C.; Chen, J. Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn's disease: A meta-analysis. *World J. Pediatr.* **2019**, *15*, 26–36.

20. Narula, N.; Dhillon, A.; Zhang, D.; Sherlock, M.E.; Tondeur, M.; Zachos, M. Enteral nutritional therapy for induction of remission in Crohn's disease. *Cochrane Database Syst. Rev.* **2018**, *4*, CD000542.

21. Swaminath, A.; Feathers, A.; Ananthakrishnan, A.N.; Falzon, L.; Li Ferry, S. Systematic review with meta-analysis: Enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. *Aliment. Pharmacol. Ther.* **2017**, *46*, 645–656.

22. Pigneur, B.; Lepage, P.; Mondot, S.; Schmitz, J.; Goulet, O.; Dore, J.; Ruemmele, F.M. Mucosal Healing and Bacterial Composition in Response to Enteral Nutrition Vs. Steroid-based Induction Therapy-A Randomised Prospective Clinical Trial in Children with Crohn's Disease. *J. Crohns Colitis* **2019**, *13*, 846–855.

23. Borrelli, O.; Cordischi, L.; Cirulli, M.; Paganelli, M.; Labalestra, V.; Uccini, S.; Russo, P.M.; Cucchiara, S. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: A randomized controlled open-label trial. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **2006**, *4*, 744–753.

24. O'Morain, C.; Segal, A.W.; Levi, A.J. Elemental diet as primary treatment of acute Crohn's disease: A controlled trial. *Br. Med. J.* **1984**, *288*, 1859–1862.

25. Okada, M.; Yao, T.; Yamamoto, T.; Takenaka, K.; Imamura, K.; Maeda, K.; Fujita, K. Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn's disease. *Hepatogastroenterology* **1990**, *37*, 72–80.

26. Gordon-Dixon, A.; Gore-Rodney, J.; Hampal, R.; Ross, R.; Miah, A.; Amorim Adegboye, A.R.; Grimes, C.E. The role of exclusive enteral nutrition in the pre-operative optimisation of adult patients with Crohn's disease. A systematic review. *Clin. Nutr. ESPEN* **2021**, *46*, 99–105.

27. Wedrychowicz, A.; Kowalska-Duplaga, K.; Jedynak-Wasowicz, U.; Pieczarkowski, S.; Sladek, M.; Tomasik, P.; Fyderek, K. Serum concentrations of VEGF and TGF-beta1 during exclusive enteral nutrition in IBD. *J. Pediatr. Gastroenterol. Nutr.* **2011**, *53*, 150–155.

28. Sahu, P.; Kedia, S.; Vuyyuru, S.K.; Bajaj, A.; Markandey, M.; Singh, N.; Singh, M.; Kante, B.; Kumar, P.; Ranjan, M.; et al. Randomised clinical trial: Exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. *Aliment. Pharmacol. Ther.* **2021**, *53*, 568–576.

29. Shaoul, R.; Brown, S.; Day, A.S. Reasoning Beyond the Potential Use of Exclusive Enteral Nutrition and Other Specified Diets in Children With Ulcerative Colitis. *J. Pediatr. Gastroenterol. Nutr.* **2018**, *66*, 378–382.

30. Logan, M.; Gkikas, K.; Svolos, V.; Nichols, B.; Milling, S.; Gaya, D.R.; Seenan, J.P.; Macdonald, J.; Hansen, R.; Ijaz, U.Z.; et al. Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn's disease-new insights into dietary disease triggers. *Aliment. Pharmacol. Ther.* **2020**, *51*, 935–947.

31. Dawson, R.; Wands, D.I.F.; Logan, M.; Bremner, G.; Efklides, S.; Benn, L.; Henderson, P.; Grant, H.; Meredith, J.; Armstrong, K.; et al. Comparing Effectiveness of a Generic Oral Nutritional Supplement With Specialized Formula in the Treatment of Active Pediatric Crohn's Disease. *Inflamm. Bowel Dis.* **2022**, *28*, 1859–1864.

32. Berni Canani, R.; Terrin, G.; Borrelli, O.; Romano, M.T.; Manguso, F.; Coruzzo, A.; D'Armiento, F.; Romeo, E.F.; Cucchiara, S. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. *Dig. Liver Dis.* **2006**, *38*, 381–387.

33. Gerasimidis, K.; Bertz, M.; Hanske, L.; Junick, J.; Biskou, O.; Aguilera, M.; Garrick, V.; Russell, R.K.; Blaut, M.; McGrogan, P.; et al. Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn's disease during enteral nutrition. *Inflamm. Bowel Dis.* **2014**, *20*, 861–871.

34. Diederen, K.; Li, J.V.; Donachie, G.E.; de Meij, T.G.; de Waart, D.R.; Hakvoort, T.B.M.; Kindermann, A.; Wagner, J.; Auyeung, V.; Te Velde, A.A.; et al. Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn's disease. *Sci. Rep.* **2020**, *10*, 18879.

35. Hoskins, L.C.; Agustines, M.; McKee, W.B.; Boulding, E.T.; Kriaris, M.; Niedermeyer, G. Mucin degradation in human colon ecosystems. Isolation and properties of fecal strains that degrade ABH blood group antigens and oligosaccharides from mucin glycoproteins. *J. Clin. Investig.* **1985**, *75*, 944–953.

36. Joossens, M.; Huys, G.; Cnockaert, M.; De Preter, V.; Verbeke, K.; Rutgeerts, P.; Vandamme, P.; Vermeire, S. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut* **2011**, *60*, 631–637. [

37. Quince, C.; Ijaz, U.Z.; Loman, N.; Eren, A.M.; Saulnier, D.; Russell, J.; Haig, S.J.; Calus, S.T.; Quick, J.; Barclay, A.; et al. Extensive Modulation of the Fecal Metagenome in Children With Crohn's Disease During Exclusive Enteral Nutrition. *Am. J. Gastroenterol.* **2015**, *110*, 1718–1729.

38. Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermudez-Humaran, L.G.; Gratadoux, J.J.; Blugeon, S.; Bridonneau, C.; Furet, J.P.; Corthier, G.; et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 16731–16736.

39. Chassaing, B.; Van de Wiele, T.; De Bodt, J.; Marzorati, M.; Gewirtz, A.T. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. *Gut* **2017**, *66*, 1414–1427.

40. Bannerjee, K.; Camacho-Hubner, C.; Babinska, K.; Dryhurst, K.M.; Edwards, R.; Savage, M.O.; Sanderson, I.R.; Croft, N.M. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. *J. Pediatr. Gastroenterol. Nutr.* **2004**, *38*, 270–275.

41. Beattie, R.M.; Camacho-Hubner, C.; Wacharasindhu, S.; Cotterill, A.M.; Walker-Smith, J.A.; Savage, M.O. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. *Clin. Endocrinol.* **1998**, *49*, 483–489.

42. Johnson, T.; Macdonald, S.; Hill, S.M.; Thomas, A.; Murphy, M.S. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: A randomised controlled trial. *Gut* **2006**, *55*, 356–361.

43. Levine, A.; Wine, E.; Assa, A.; Sigall Boneh, R.; Shaoul, R.; Kori, M.; Cohen, S.; Peleg, S.; Shamaly, H.; On, A.; et al. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. *Gastroenterology* **2019**, *157*, 440–450.e448.

44. Sigall-Boneh, R.; Pfeffer-Gik, T.; Segal, I.; Zangen, T.; Boaz, M.; Levine, A. Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. *Inflamm. Bowel Dis.* **2014**, *20*, 1353–1360.

45. Yanai, H.; Levine, A.; Hirsch, A.; Boneh, R.S.; Kopylov, U.; Eran, H.B.; Cohen, N.A.; Ron, Y.; Goren, I.; Leibovitzh, H.; et al. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): An open-label, pilot, randomised trial. *Lancet Gastroenterol. Hepatol.* **2022**, *7*, 49–59.

46. Sigall Boneh, R.; Sarbagili Shabat, C.; Yanai, H.; Chermesh, I.; Ben Avraham, S.; Boaz, M.; Levine, A. Dietary Therapy wth the Crohn's Disease Exclusion Diet is a Successful Strategy for Induction of Remission in Children and Adults Failing Biological Therapy. *J. Crohns Colitis* **2017**, *11*, 1205–1212.

47. Verburgt, C.M.; Dunn, K.A.; Ghiboub, M.; Lewis, J.D.; Wine, E.; Sigall Boneh, R.; Gerasimidis, K.; Shamir, R.; Penny, S.; Pinto, D.M.; et al. Successful Dietary Therapy in Paediatric Crohn's Disease is Associated with Shifts in Bacterial Dysbiosis and Inflammatory Metabotype Towards Healthy Controls. *J. Crohns Colitis* **2022**, *17*, 61–72.

48. Ghiboub, M.; Penny, S.; Verburgt, C.M.; Boneh, R.S.; Wine, E.; Cohen, A.; Dunn, K.A.; Pinto, D.M.; Benninga, M.A.; de Jonge, W.J.; et al. Metabolome Changes with Diet-Induced Remission in Pediatric Crohn's Disease. *Gastroenterology* **2022**, *163*, 922–936.e915.

49. Levine, A.; Rhodes, J.M.; Lindsay, J.O.; Abreu, M.T.; Kamm, M.A.; Gibson, P.R.; Gasche, C.; Silverberg, M.S.; Mahadevan, U.; Boneh, R.S.; et al. Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **2020**, *18*, 1381–1392.

50. Suskind, D.L.; Wahbeh, G.; Cohen, S.A.; Damman, C.J.; Klein, J.; Braly, K.; Shaffer, M.; Lee, D. Patients Perceive Clinical Benefit with the Specific Carbohydrate Diet for Inflammatory Bowel Disease. *Dig. Dis. Sci.* **2016**, *61*, 3255–3260.

51. Suskind, D.L.; Wahbeh, G.; Gregory, N.; Vendettuoli, H.; Christie, D. Nutritional therapy in pediatric Crohn disease: The specific carbohydrate diet. *J. Pediatr. Gastroenterol. Nutr.* **2014**, *58*, 87–91.

52. Cohen, S.A.; Gold, B.D.; Oliva, S.; Lewis, J.; Stallworth, A.; Koch, B.; Eshee, L.; Mason, D. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. *J. Pediatr. Gastroenterol. Nutr.* **2014**, *59*, 516–521.

53. Obih, C.; Wahbeh, G.; Lee, D.; Braly, K.; Giefer, M.; Shaffer, M.L.; Nielson, H.; Suskind, D.L. Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. *Nutrition* **2016**, *32*, 418–425.

54. Suskind, D.L.; Cohen, S.A.; Brittnacher, M.J.; Wahbeh, G.; Lee, D.; Shaffer, M.L.; Braly, K.; Hayden, H.S.; Klein, J.; Gold, B.; et al. Clinical and Fecal Microbial Changes With Diet Therapy in Active Inflammatory Bowel Disease. *J. Clin. Gastroenterol.* **2018**, *52*, 155–163.

55. Suskind, D.L.; Lee, D.; Kim, Y.M.; Wahbeh, G.; Singh, N.; Braly, K.; Nuding, M.; Nicora, C.D.; Purvine, S.O.; Lipton, M.S.; et al. The Specific Carbohydrate Diet and Diet Modification as Induction Therapy for Pediatric Crohn's Disease: A Randomized Diet Controlled Trial. *Nutrients* **2020**, *12*, 3749.

56. Kaplan, H.C.; Opipari-Arrigan, L.; Yang, J.; Schmid, C.H.; Schuler, C.L.; Saeed, S.A.; Braly, K.L.; Chang, F.; Murphy, L.; Dodds, C.M.; et al. Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease: A Series of N-of-1 Diet Trials. *Am. J. Gastroenterol.* **2022**, *117*, 902–917.

57. Lewis, J.D.; Sandler, R.S.; Brotherton, C.; Brensinger, C.; Li, H.; Kappelman, M.D.; Daniel, S.G.; Bittinger, K.; Albenberg, L.; Valentine, J.F.; et al. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults with Crohn's Disease. *Gastroenterology* **2021**, *161*, 837–852.

58. Sarbagili Shabat, C.; Scaldaferri, F.; Zittan, E.; Hirsch, A.; Mentella, M.C.; Musca, T.; Cohen, N.A.; Ron, Y.; Fliss Isakov, N.; Pfeffer, J.; et al. Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial. *J. Crohns Colitis* **2022**, *16*, 369–378.

59. Pedersen, N.; Ankersen, D.V.; Felding, M.; Wachmann, H.; Vegh, Z.; Molzen, L.; Burisch, J.; Andersen, J.R.; Munkholm, P. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. *World J. Gastroenterol.* **2017**, *23*, 3356–3366.

60. Prince, A.C.; Myers, C.E.; Joyce, T.; Irving, P.; Lomer, M.; Whelan, K. Fermentable Carbohydrate Restriction (Low FODMAP Diet) in Clinical Practice Improves Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease. *Inflamm. Bowel Dis.* **2016**, *22*, 1129–1136.

61. Bodini, G.; Zanella, C.; Crespi, M.; Lo Pumo, S.; Demarzo, M.G.; Savarino, E.; Savarino, V.; Giannini, E.G. A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. *Nutrition* **2019**, *67-68*, 110542.

62. Cox, S.R.; Prince, A.C.; Myers, C.E.; Irving, P.M.; Lindsay, J.O.; Lomer, M.C.; Whelan, K. Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial. *J. Crohns Colitis* **2017**, *11*, 1420–1429.

63. Cox, S.R.; Lindsay, J.O.; Fromentin, S.; Stagg, A.J.; McCarthy, N.E.; Galleron, N.; Ibraim, S.B.; Roume, H.; Levenez, F.; Pons, N.; et al. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial. *Gastroenterology* **2020**, *158*, 176–188.e177.

64. So, D.; Loughman, A.; Staudacher, H.M. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: A systematic review with meta-analysis. *Am. J. Clin. Nutr.* **2022**, *116*, 943–952.

65. Peng, Z.; Yi, J.; Liu, X. A Low-FODMAP Diet Provides Benefits for Functional Gastrointestinal Symptoms but Not for Improving Stool Consistency and Mucosal Inflammation in IBD: A Systematic Review and Meta-Analysis. *Nutrients* **2022**, *14*, 2072.

66. Tang, C.; Wang, X.; Qin, L.Q.; Dong, J.Y. Mediterranean Diet and Mortality in People with Cardiovascular Disease: A Meta-Analysis of Prospective Cohort Studies. *Nutrients* **2021**, *13*, 2623.

67. Mentella, M.C.; Scaldaferri, F.; Ricci, C.; Gasbarrini, A.; Miggiano, G.A.D. Cancer and Mediterranean Diet: A Review. *Nutrients* **2019**, *11*, 2059.

68. Chicco, F.; Magri, S.; Cingolani, A.; Paduano, D.; Pesenti, M.; Zara, F.; Tumbarello, F.; Urru, E.; Melis, A.; Casula, L.; et al. Multidimensional Impact of Mediterranean Diet on IBD Patients. *Inflamm. Bowel Dis.* **2021**, *27*, 1–9.

69. Godny, L.; Reshef, L.; Pfeffer-Gik, T.; Goren, I.; Yanai, H.; Tulchinsky, H.; Gophna, U.; Dotan, I. Adherence to the Mediterranean diet is associated with decreased fecal calprotectin in patients with ulcerative colitis after pouch surgery. *Eur. J. Nutr.* **2020**, *59*, 3183–3190.

70. Strisciuglio, C.; Cenni, S.; Serra, M.R.; Dolce, P.; Martinelli, M.; Staiano, A.; Miele, E. Effectiveness of Mediterranean Diet's Adherence in children with Inflammatory Bowel Diseases. *Nutrients* **2020**, *12*, 3206

71. Reznikov, E. A., & Suskind, D. L. (2023). Current nutritional therapies in inflammatory bowel disease: improving clinical remission rates and sustainability of long-term dietary therapies. *Nutrients*, *15*(3), 668.

الملخص:

الخلفية: مرض الأمعاء الالتهابي(IBD) ، بما في ذلك مرض كرون (CD) والتهاب القولون التقرحي(UC) ، هو اضطراب مزمن مناعي المنشأ يتميز بالتهاب في الجهاز الهضمي. أصبح من المعترف به بشكل متزايد أن العلاقة بين النظام الغذائي، ميكروبيوتا الأمعاء، والاستجابة المناعية تشكل عاملاً رئيسياً في تطور وإدارة مرض الأمعاء الالتهابي. يعتقد أن النظام الغذائي الغربي، الغني بالدهون، السكريات، والإضافات، يساهم في تقدم مرض الأمعاء الالتهابي. تستعرض هذه المقالة التدخلات الغذائية التي تهدف إلى تعديل الالتهاب المعوي، مع التركيز على دورها في إدارة مرض الأمعاء الالتهابي.

الهدف: يهدف هذا المقال إلى تقييم فعالية العلاجات الغذائية، مثل التغذية الأنبوبية الحصرية(EEN) ، والتغذية الأنبوبية الجزئية(PEN) ، واتباع النظام الغذائي لاستبعاد مرض كرون(CDED) ، في إدارة مرض الأمعاء الالتهابي، مع التركيز بشكل خاص على تأثيرها في الالتهاب، وتركيب الميكروبيوتا، والنتائج السريرية.

الطرق: تم إجراء بحث شامل في سجلات التجارب السريرية وقاعدة بيانات PUBMED لتحديد الدراسات ذات الصلة بالتدخلات الغذائية لمرض الأمعاء الالتهابي. تشمل المراجعة تجارب مقارنة بين العلاجات الغذائية والعلاجات القياسية، والعلاج الوهمي، والتدخلات الأخرى، مع التركيز على التخفيف السريري، وشفاء الأغشية المخاطية، والتغيرات في الميكروبات.

النتائج: أظهرت التغذية الأنبوبية الحصرية (EEN) فعالية قوية في إحداث التخفيف لدى مرضى مرض كرون في الأطفال، مع معدلات أعلى من شفاء الأغشية المخاطية مقارنة بالكورتيكوستيرويدات. في حين أن التغذية الأنبوبية الجزئية (PEN) مع النظام الغذائي لاستبعاد مرض كرون (CDED) أظهرت معدلات تخفيف مماثلة للتغذية الأنبوبية الحصرية(EEN) ، إلا أنها تقدم مزايا في تحمل المرضى والإدارة طويلة الأجل. بالإضافة إلى ذلك، ارتبطت التغيرات الغذائية بتغيرات في ميكروبيوتا الأمعاء، خصوصاً انخفاض تنوع الميكروبات والتغيرات في بعض الأنواع البكتيرية، والتي ترتبط بتحسن سريري.

الخلاصة: التدخلات الغذائية، وخاصة التغذية الأنبوبية الحصرية (EEN) والتغذية الأنبوبية الجزئية (PEN) مع النظام الغذائي لاستبعاد مرض كرون (CDED)، هي علاجات واعدة لمرض الأمعاء الالتهابي، وتوفر فوائد كبيرة في إدارة الالتهاب وتعزيز شفاء الأغشية المخاطية. هناك حاجة إلى مزيد من البحث لتحسين هذه الاستراتيجيات الغذائية للإدارة على المدى القصير والطويل لمرض الأمعاء الالتهابي.

الكلمات المفتاحية: مرض الأمعاء الالتهابي، مرض كرون، التهاب القولون التقرحي، التغذية الأنبوبية الحصرية، التغذية الأنبوبية الجزئية، النظام الغذائي لاستبعاد مرض كرون، الميكروبيوتا، الالتهاب.